A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
NCT ID: NCT02684097
Last Updated: 2020-01-07
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
22 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-01-31
Study Completion Date
2017-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess whether tralokinumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp. Expected is 50% of these subjects to have concomitant alopecia areata (AA) and atopic dermatitis (AD). Subjects with AA alone (15 subjects) will be randomized (2:1) to either receive tralokinumab or placebo via subcutaneous injection every 2 weeks for 24 weeks. Subjects with concomitant alopecia areata and atopic dermatitis (15 subjects) will be randomized separately in a 2:1 ratio to receive tralokinumab or placebo via subcutaneous injection every 2 weeks for 24 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
NCT01950780
Alopecia Areata
COMPLETED
PHASE2
Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
NCT02684123
Alopecia Areata
COMPLETED
NA
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
NCT03359356
Alopecia Areata
COMPLETED
PHASE2
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
NCT03532958
Alopecia Areata
Alopecia Totalis
Alopecia Universalis
WITHDRAWN
PHASE2
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748
Alopecia Areata
Alopecia Totalis
Alopecia Universalis
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to assess whether tralokinumab can be a helpful treatment for alopecia areata.
This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp. The researchers expect 50% of these subjects to have concomitant alopecia areata (AA) and atopic dermatitis (AD).
The researchers' experience in AD12-14, and past experience in psoriasis15, 16 showed that biomarker studies in skin tissues are critical to the understanding of key pathogenic pathways that are upregulated in each disease and how well they are suppressed with effective treatment. These mechanistic studies coupled with clinical trials are key in the disease to shed light on important disease mechanisms, and to explain which molecules are suppressed by each therapeutic target. Data shows that IL-13 is significantly upregulated in both AD and AA lesions compared to nonlesional skin. It is very important to associate the clinical responses with suppression of this cytokine and related molecules as well as other pathway cytokines in skin tissues. Both the whole genomic profiling and individual molecular and cellular markers are very important in order to understand how well anti-IL-13 will change/suppress AA-associated pathways and compare with those that will be suppressed in AD.
Since this study is designed to gain basic knowledge rather than to yield information directly related to patient care, the results are not entered in the participants' medical records. If, at a later date, correlations of in-vitro tests and the patients' clinical situation suggest that the results do bear on the patients' health, an amended protocol will be submitted to the IRB so that results can be made available to the medical record.
This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp. The researchers expect 50% of these subjects to have concomitant alopecia areata (AA) and atopic dermatitis (AD).
The researchers' experience in AD12-14, and past experience in psoriasis15, 16 showed that biomarker studies in skin tissues are critical to the understanding of key pathogenic pathways that are upregulated in each disease and how well they are suppressed with effective treatment. These mechanistic studies coupled with clinical trials are key in the disease to shed light on important disease mechanisms, and to explain which molecules are suppressed by each therapeutic target. Data shows that IL-13 is significantly upregulated in both AD and AA lesions compared to nonlesional skin. It is very important to associate the clinical responses with suppression of this cytokine and related molecules as well as other pathway cytokines in skin tissues. Both the whole genomic profiling and individual molecular and cellular markers are very important in order to understand how well anti-IL-13 will change/suppress AA-associated pathways and compare with those that will be suppressed in AD.
Since this study is designed to gain basic knowledge rather than to yield information directly related to patient care, the results are not entered in the participants' medical records. If, at a later date, correlations of in-vitro tests and the patients' clinical situation suggest that the results do bear on the patients' health, an amended protocol will be submitted to the IRB so that results can be made available to the medical record.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alopecia Areata
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tralokinumab
Tralokinumab subcutaneous injection every two weeks for 24 weeks
Group Type
ACTIVE_COMPARATOR
Tralokinumab
Intervention Type
DRUG
All groups will receive study drug every two weeks for 24 weeks.
Placebo
Saline subcutaneous injection every two weeks for 24 weeks.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Matching placebo given every two weeks for 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tralokinumab
All groups will receive study drug every two weeks for 24 weeks.
Intervention Type
DRUG
Placebo
Matching placebo given every two weeks for 24 weeks
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Saline subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, aged from 18 to 75 years, inclusively at the time of signing the informed consent document.
* Subject has provided written informed consent prior to any study specific procedures.
* Body weight of ≥40 and \<150 kg at enrollment.
* Subject has a history of alopecia areata for at least 3 months.
* Subject has extensive patchy alopecia areata (at least 30% scalp hair loss).
* No evidence of hair regrowth at Baseline.
* For WOCBP only: have a negative urine pregnancy test prior to administration of the IP.
* For inclusion in the voluntary pharmacogenetic research, subjects should fulfill the following criterion: Provision of a signed and dated written informed consent for the pharmacogenetic sample and analysis. If a subject declines to participate in the pharmacogenetic research, there will be no consequence or loss of benefit to the subject. The subject will not be excluded from the other aspects of the study described in the protocol, as long as they consent to participate in the study.
* Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination performed at Screening.
* Subjects may be naïve to treatment or unresponsive to intralesional steroids or other treatments for alopecia areata.
* Subject has provided written informed consent prior to any study specific procedures.
* Body weight of ≥40 and \<150 kg at enrollment.
* Subject has a history of alopecia areata for at least 3 months.
* Subject has extensive patchy alopecia areata (at least 30% scalp hair loss).
* No evidence of hair regrowth at Baseline.
* For WOCBP only: have a negative urine pregnancy test prior to administration of the IP.
* For inclusion in the voluntary pharmacogenetic research, subjects should fulfill the following criterion: Provision of a signed and dated written informed consent for the pharmacogenetic sample and analysis. If a subject declines to participate in the pharmacogenetic research, there will be no consequence or loss of benefit to the subject. The subject will not be excluded from the other aspects of the study described in the protocol, as long as they consent to participate in the study.
* Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination performed at Screening.
* Subjects may be naïve to treatment or unresponsive to intralesional steroids or other treatments for alopecia areata.
Exclusion Criteria
* History of male or female pattern hair loss Ludwig stage III or Hamilton \> stage V.
* Subjects in whom the diagnosis of alopecia areata is in question.
* Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
1. Affect the safety of the subject throughout the study
2. Influence the findings of the studies or their interpretations
3. Impede the subject's ability to complete the entire duration of study
* Known history of allergy or reaction to any component of the IP formulation.
* History of anaphylaxis following any biologic therapy.
* The following treatments within 4 weeks before the Baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) at any time during the study:
1. Systemic corticosteroids
2. Immunosuppressive/immunomodulating drugs (eg, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase (JAK) inhibitors, azathioprine or methotrexate), Ultra-Violet (UV) B phototherapy; and/or Psoralen Ultra-Violet A (PUVA) therapy.
* Treatment with topical corticosteroids, tacrolimus and/or pimecrolimus within 1 week before the Baseline visit.
* Subject has taken enzyme-modifying drugs that are moderate inhibitors/potent inducers of cytochrome P450 3A4 or potent inhibitors of cytochrome P450 2C19 enzymes (such as cimetidine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole etc…) and strong inducers of CYP enzymes (such as rifampin etc…), in the previous 28 days before day 0.
* A helminth parasitic infection diagnosed within 6 months prior to the date informed consent or assent obtained that has not been treated with, or has failed to respond to, standard of care therapy.
* History of clinically significant infection, including acute upper or lower respiratory infections, requiring antibiotics or antiviral medication within 30 days prior to the date informed consent or assent is obtained or during the run-in period.
* Tuberculosis requiring treatment within the 12 months prior to enrolment (Visit 1).
* Any clinically significant abnormal findings in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis during the run-in period, which in the opinion of the Investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to complete entire duration of the study.
* History of chronic alcohol or drug abuse within 12 months of the enrolment visit, or a condition associated with poor compliance as judged by the Investigator.
* Positive hepatitis B surface antigen or hepatitis C virus antibody serology. Subjects with a history of hepatitis B vaccination without a history of hepatitis B are allowed to be enrolled.
* History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at enrolment, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report.
* Current tobacco smoking (smoking must have stopped for ≥ 3 months prior to enrollment) or a history of tobacco smoking for ≥ 10 pack-years (one pack year = 20 cigarettes smoked per day for 1 year).
* History of cancer: - Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained
* Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, systemic corticosteroids including regular treatment with OCS or intramuscular long-acting depot corticosteroids, or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent or assent is obtained.
* Clinically significant asthma exacerbation, in the opinion of the Investigator, including those requiring use of oral corticosteroids 30 days prior to the date of informed consent or during the screening/run-in period.
* Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent or assent is obtained.
* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to the enrolment visit, whichever is longer.
* Receipt of live attenuated vaccines 30 days prior to the date of randomization and during the study including the follow-up period Receipt of inactive/killed vaccinations (eg, inactive influenza) are allowed, provided they are not administered within 5 days before/after any study visit.
* Receipt of any investigational non-biologic agent within 30 days or 5 half lives prior to informed consent or assent being obtained, whichever is longer.
* Previous receipt of tralokinumab (CAT-354).
* Initiation of new allergen immunotherapy or change in existing immunotherapy is not allowed within 30 days prior to the date of informed consent. However allergen immunotherapy initiated prior to this period may be continued provided there is a span of at least 5 days between the immunotherapy and IP administration.
* Current use of oral or ophthalmic non-selective β-adrenergic antagonist (eg, propranolol).
* Current use of five- lipoxygenase inhibitors (eg, Zileuton) or roflumilast.
* Major surgery within 8 weeks prior to the enrolment visit, or planned in-subject surgery or hospitalization during the study period.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times the upper limit of normal (ULN) at enrolment
* Pregnant, currently breast-feeding, or lactating women.
* Previous randomization in the present study.
* Concurrent enrollment in another clinical study where the subject is receiving an IP.
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
* Employees of the clinical study site or any other individuals directly involved with the planning or conduct of the study, or immediate family members of such individuals.
* Individuals who are legally institutionalized.
For exclusion from the voluntary pharmacogenetic research:
* Previous allogeneic bone marrow transplant.
* Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.
* Subjects in whom the diagnosis of alopecia areata is in question.
* Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
1. Affect the safety of the subject throughout the study
2. Influence the findings of the studies or their interpretations
3. Impede the subject's ability to complete the entire duration of study
* Known history of allergy or reaction to any component of the IP formulation.
* History of anaphylaxis following any biologic therapy.
* The following treatments within 4 weeks before the Baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) at any time during the study:
1. Systemic corticosteroids
2. Immunosuppressive/immunomodulating drugs (eg, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase (JAK) inhibitors, azathioprine or methotrexate), Ultra-Violet (UV) B phototherapy; and/or Psoralen Ultra-Violet A (PUVA) therapy.
* Treatment with topical corticosteroids, tacrolimus and/or pimecrolimus within 1 week before the Baseline visit.
* Subject has taken enzyme-modifying drugs that are moderate inhibitors/potent inducers of cytochrome P450 3A4 or potent inhibitors of cytochrome P450 2C19 enzymes (such as cimetidine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole etc…) and strong inducers of CYP enzymes (such as rifampin etc…), in the previous 28 days before day 0.
* A helminth parasitic infection diagnosed within 6 months prior to the date informed consent or assent obtained that has not been treated with, or has failed to respond to, standard of care therapy.
* History of clinically significant infection, including acute upper or lower respiratory infections, requiring antibiotics or antiviral medication within 30 days prior to the date informed consent or assent is obtained or during the run-in period.
* Tuberculosis requiring treatment within the 12 months prior to enrolment (Visit 1).
* Any clinically significant abnormal findings in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis during the run-in period, which in the opinion of the Investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to complete entire duration of the study.
* History of chronic alcohol or drug abuse within 12 months of the enrolment visit, or a condition associated with poor compliance as judged by the Investigator.
* Positive hepatitis B surface antigen or hepatitis C virus antibody serology. Subjects with a history of hepatitis B vaccination without a history of hepatitis B are allowed to be enrolled.
* History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at enrolment, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report.
* Current tobacco smoking (smoking must have stopped for ≥ 3 months prior to enrollment) or a history of tobacco smoking for ≥ 10 pack-years (one pack year = 20 cigarettes smoked per day for 1 year).
* History of cancer: - Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained
* Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, systemic corticosteroids including regular treatment with OCS or intramuscular long-acting depot corticosteroids, or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent or assent is obtained.
* Clinically significant asthma exacerbation, in the opinion of the Investigator, including those requiring use of oral corticosteroids 30 days prior to the date of informed consent or during the screening/run-in period.
* Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent or assent is obtained.
* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to the enrolment visit, whichever is longer.
* Receipt of live attenuated vaccines 30 days prior to the date of randomization and during the study including the follow-up period Receipt of inactive/killed vaccinations (eg, inactive influenza) are allowed, provided they are not administered within 5 days before/after any study visit.
* Receipt of any investigational non-biologic agent within 30 days or 5 half lives prior to informed consent or assent being obtained, whichever is longer.
* Previous receipt of tralokinumab (CAT-354).
* Initiation of new allergen immunotherapy or change in existing immunotherapy is not allowed within 30 days prior to the date of informed consent. However allergen immunotherapy initiated prior to this period may be continued provided there is a span of at least 5 days between the immunotherapy and IP administration.
* Current use of oral or ophthalmic non-selective β-adrenergic antagonist (eg, propranolol).
* Current use of five- lipoxygenase inhibitors (eg, Zileuton) or roflumilast.
* Major surgery within 8 weeks prior to the enrolment visit, or planned in-subject surgery or hospitalization during the study period.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times the upper limit of normal (ULN) at enrolment
* Pregnant, currently breast-feeding, or lactating women.
* Previous randomization in the present study.
* Concurrent enrollment in another clinical study where the subject is receiving an IP.
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
* Employees of the clinical study site or any other individuals directly involved with the planning or conduct of the study, or immediate family members of such individuals.
* Individuals who are legally institutionalized.
For exclusion from the voluntary pharmacogenetic research:
* Previous allogeneic bone marrow transplant.
* Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emma Guttman
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emma Guttman
Associate Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emma Guttman, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
ISMMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Alkhalifah A. Alopecia areata update. Dermatol Clin. 2013 Jan;31(1):93-108. doi: 10.1016/j.det.2012.08.010. Epub 2012 Oct 2.
Reference Type
BACKGROUND
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995 Jul;70(7):628-33. doi: 10.4065/70.7.628.
Reference Type
BACKGROUND
Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013 Jul;149(7):789-94. doi: 10.1001/jamadermatol.2013.3049.
Reference Type
BACKGROUND
Betz RC, Pforr J, Flaquer A, Redler S, Hanneken S, Eigelshoven S, Kortum AK, Tuting T, Lambert J, De Weert J, Hillmer AM, Schmael C, Wienker TF, Kruse R, Lutz G, Blaumeiser B, Nothen MM. Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease. J Invest Dermatol. 2007 Nov;127(11):2539-43. doi: 10.1038/sj.jid.5700915. Epub 2007 Jun 21.
Reference Type
BACKGROUND
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE Jr, McMichael AJ, Randall VA, Turner ML, Sperling L, Whiting DA, Norris D; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004 Sep;51(3):440-7. doi: 10.1016/j.jaad.2003.09.032. No abstract available.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCO 15-1497
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Secukinumab for the Treatment of Alopecia Areata
NCT02599129
TERMINATED
PHASE2
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
NCT02299297
COMPLETED
PHASE2
The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata
NCT01246284
COMPLETED
NA
Intralesional Steroids in the Treatment of Alopecia Areata
NCT01898806
TERMINATED
PHASE4
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT02553330
TERMINATED
PHASE2
Dupilumab in the Treatment of Pediatric Alopecia Areata
NCT05866562
RECRUITING
PHASE2
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
NCT00484679
COMPLETED
PHASE2
A Study of JNJ-64304500 in Participants With Alopecia Areata
NCT04740970
WITHDRAWN
PHASE2
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
NCT01917058
WITHDRAWN
PHASE2
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
NCT06088147
NOT_YET_RECRUITING
NA
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240
RECRUITING
PHASE3
Regeneron AA Multicenter (Dupilumab)
NCT05551793
RECRUITING
PHASE2
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02312882
COMPLETED
NA
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02812342
COMPLETED
PHASE2
Tofacitnib for the Treatment of Alopecia Areata and Variants
NCT02197455
COMPLETED
PHASE2
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
NCT05368103
COMPLETED
PHASE2
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
NCT00063076
COMPLETED
PHASE2/PHASE3
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196
RECRUITING
PHASE1/PHASE2
Topical Crisaborole in Patients with Alopecia Areata
NCT04299503
WITHDRAWN
PHASE2
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
NCT02018042
COMPLETED
PHASE2
The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade
NCT02037191
COMPLETED
PHASE3
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata
NCT04147845
COMPLETED
NA
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
NCT05556265
TERMINATED
PHASE2